Associated Papers
Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.
Allsopp RC et al.
Bmc Cancer, 2025
ESR1 ctDNA testing: literature review and comparison of assays for ESR1 mutation detection in advanced hormone receptor-positive breast cancer.
Yarunin A et al.
Expert Review of Molecular Diagnostics, 2025
Evolutionary Overview and Future Perspectives: ESR1 Mutations, Liquid Biopsy, and Artificial Intelligence for a New Era of Personalized Medicine in ER+ Breast Cancer.
Martella S et al.
Molecular Diagnosis & Therapy, 2025
Detection of ESR1 Mutations in Tissue and Liquid Biopsy with Novel Next-Generation Sequencing and Digital Droplet PCR Assays: Insights from Multi-Center Real Life Data of Almost 6000 Patients.
Borkar S et al.
Cancers, 2025
Somatic estrogen receptor α mutations that induce dimerization promote receptor activity and breast cancer proliferation.
Irani S et al.
The Journal of Clinical Investigation, 2024
Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2.
Damodaran S et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2023
Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial.
Goetz MP et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2023
ESR1 Gene Mutations and Liquid Biopsy in ER-Positive Breast Cancers: A Small Step Forward, a Giant Leap for Personalization of Endocrine Therapy?
Betz M et al.
Cancers, 2023
ESR1 activating mutations: From structure to clinical application.
Grinshpun A et al.
Biochimica Et Biophysica Acta. Reviews on Cancer, 2023
Estrogen Receptor Alpha and ESR1 Mutations in Breast Cancer.
Patel JM et al.
Advances in Experimental Medicine and Biology, 2022
Estrogen receptor-α signaling in post-natal mammary development and breast cancers.
Rusidzé M et al.
Cellular and Molecular Life Sciences : Cmls, 2021
Fusion Genes in Breast Cancer.
Kim J et al.
Advances in Experimental Medicine and Biology, 2021
Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket Study.
Smyth LM et al.
Jco Precision Oncology, 2021
Phase and context shape the function of composite oncogenic mutations.
Gorelick AN et al.
Nature, 2020
Standardization of Somatic Variant Classifications in Solid and Haematological Tumours by a Two-Level Approach of Biological and Clinical Classes: An Initiative of the Belgian ComPerMed Expert Panel.
Froyen G et al.
Cancers, 2019
Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis.
O'Leary B et al.
Clinical Chemistry, 2019
Targeted mutation detection in breast cancer using MammaSeq™.
Smith NG et al.
Breast Cancer Research : Bcr, 2019
The Impact of ESR1 Mutations on the Treatment of Metastatic Breast Cancer.
Pejerrey SM et al.
Hormones & Cancer, 2018
Implications of ESR1 Mutations in Hormone Receptor-Positive Breast Cancer.
Reinert T et al.
Current Treatment Options in Oncology, 2018
Are We Ready to Use ESR1 Mutations in Clinical Practice?
Jeselsohn R
Breast Care (basel, Switzerland), 2017
The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer.
Jeselsohn R et al.
Current Oncology Reports, 2017
Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.
Toy W et al.
Cancer Discovery, 2017
Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer.
Mu Z et al.
International Journal of Molecular Sciences, 2016
Are Estrogen Receptor Genomic Aberrations Predictive of Hormone Therapy Response in Breast Cancer?
Tabarestani S et al.
Iranian Journal of Cancer Prevention, 2016
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.
Spoerke JM et al.
Nature Communications, 2016
ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer.
Jeselsohn R et al.
Nature Reviews. Clinical Oncology, 2015
Estrogen receptor mutations and their role in breast cancer progression.
Alluri PG et al.
Breast Cancer Research : Bcr, 2014
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.
Toy W et al.
Nature Genetics, 2013